From: Nanoparticles advanced from preclinical studies to clinical trials for lung cancer therapy
Target | Effects on the organism | Drugs | Limitations | References |
---|---|---|---|---|
EGFR | A key factor in cell proliferation, differentiation, division, survival, and cancer development | I: Gefitinib,Erlotinib,Icotinib | Produce limitations, and the third-generation drug Osimertinib has severe toxicity | (Ye et al. 2021) |
II: Afatinib,Dacomitinib | ||||
III: Osimertinib | ||||
ALK | Control of cell cycle cell growth cell differentiation and anti-apoptosis | I: Crizotinib | Develops drug resistance, relapses after 9 months, and leads to liver failure | (Rodak et al. 2021) |
II: Ceritinib, Alectinib, Brigatinib | ALK point mutations lead to drug resistance | |||
III: Lorlatinib | Significant side effects, 80% produce hypercholesterolemia | |||
ROS1 | Regulation of cell growth and differentiation | Crizotinib Entretinib, lorlatinib | Low efficacy and high side effects, including neurological and cardiovascular disease | (Patil et al. 2018) |
MET | MET proliferation, mutation, and fusion are associated with related tumorigenesis | Capmatinib, Tepotinib | Low response to treatment and mutations leading to drug resistance | (Mitiushkina et al. 2019) |
RET | Mutations cause NSCLC to develop | Cabozantinib, vandetanib, sunitinib | Low response rate and low survival | (Rodak et al. 2021) |
NTRK1 | Regulation of cell growth and differentiation | Entretinib larotrectinib | Low response rate, no data on drug resistance yet | (Imyanitov et al. 2021) |